Table 3 |
|||||||
|
End-stage renal disease and albuminuria associations with p.R229Q in different diabetic cohorts |
|||||||
|
N = 280 |
Type I (n = 41) |
Type 2 (n = 239) |
Total (n = 280) |
||||
|
|
|||||||
|
Utah diabetes study |
No ESRD (n = 171) |
21 p.R229R |
0 p.R229Q |
140 p.R229R |
10 p.R229Q |
161 p.R229R |
10 p.R229Q |
|
ESRD (n = 109) |
17 p.R229R |
3 p.R229Q (χ2 3.40, p = 0.07) |
82 p.R229R |
7 p.R229Q (2%) (χ2 0.12, p = 0.73) |
99 p.R229R |
10 p.R229Q (2%) (χ2 1.11, p = 0.29) |
|
|
N = 1,279 |
Type I (n = 1,279) |
Type 2 - |
Total - |
||||
|
GoKinD |
No ESRD (n = 824) |
759 p.R229R |
65 p.R229Q |
- |
- |
- |
- |
|
ESRD (n = 455) |
428 p.R229R |
p.27 R229Q (χ2 1.68, p = 0.20) |
- |
- |
- |
- |
|
|
N = 429 |
Type I (n = 67) |
Type 2 (n = 357) |
Total (n = 429) |
||||
|
Australian endocrine |
Normo (n = 279) |
47 p.R229R |
4 p.R229Q |
206 p.R229R |
22 p.R229Q |
253 p.R229R |
26 p.R229Q |
|
Micro (n = 93) |
8 p.R229R |
2 p.R229Q (χ2 1.39, p = 0.24) |
77 p.R229R |
6 p.R229Q (2%) (χ2 0.44, p = 0.51) |
85 p.R229R |
8 p.R229Q (2%) (χ2 0.04, p = 0.84) |
|
|
Macro (n = 52) |
6 p.R229R |
0 p.R229Q (χ2 0.5, p = 0.48) |
42 p.R229R |
4 p.R229Q (2%) (χ2 0.04, p = 0.84) |
48 p.R229R |
4 p.R229Q (2%) (χ2 0.14, p = 0.71) |
|
|
Micro- or Macro (n = 145) |
14 p.R229R |
2 p.R229Q (χ2 0.32, p = 0.57) |
119 p.R229R |
10 p.R229Q (2%) (χ2 0.36, p = 0.55) |
133 p.R229R |
12 p.R229Q (2%) (χ2 0.13, p = 0.72) |
|
|
|
|||||||
|
The frequency of p.R229Q in patients with type 1 or type 2 diabetes with end-stage renal disease (ESRD) was compared to those without for the Utah diabetes study and Genetics of Kidney Disease in Diabetes (GoKinD) participants. Likewise, the frequency of p.R229Q in patients with microalbuminuria (Micro) or macroalbuminuria (Macro) was compared with the frequency of normoalbuminuria (Normo) in patients with type 1 or type 2 diabetes in the Australian endocrine patients. No associations were found. |
|||||||
|
Tonna et al. BMC Nephrology 2008 9:13 doi:10.1186/1471-2369-9-13 |
|||||||
